HC Wainwright Predicts Reduced Earnings for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Gossamer Bio in a research note issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Separately, Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Gossamer Bio has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Down 4.2 %

Shares of Gossamer Bio stock opened at $1.36 on Thursday. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.55. The company has a market capitalization of $308.18 million, a price-to-earnings ratio of -4.25 and a beta of 1.86. The business has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $0.98. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in GOSS. Graham Capital Management L.P. purchased a new position in Gossamer Bio during the 4th quarter valued at about $32,000. Fullcircle Wealth LLC bought a new position in shares of Gossamer Bio during the fourth quarter valued at $43,000. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio during the third quarter valued at $67,000. Velan Capital Investment Management LP bought a new position in Gossamer Bio during the fourth quarter valued at approximately $68,000. Finally, Bank of America Corp DE boosted its holdings in Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after purchasing an additional 43,866 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.